Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients

Journal of Diabetes

Volumn 4, Issue 2, 2012, Pages 181-185

  Bunck, Mathijs C ^a   Poelma, Marieke ^a   Eekhoff, E Marelise ^a   Schweizer, Anja ^b   Heine, Robert J ^a,c   Nijpels, Giel ^a   Foley, James E ^b   Diamant, Michaela ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Bone metabolism; Cross linked C terminal telopeptide; Dipeptidylpeptidase (DPP) 4 inhibitor; Randomized clinical trial; Type 2 diabetes; Vildagliptin

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PHOSPHATE; PLACEBO; VILDAGLIPTIN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; FEMALE; FOOD INTAKE; HUMAN; HYPERGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION;

ADAMANTANE; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BONE AND BONES; BONE RESORPTION; CALCIUM; COLLAGEN TYPE I; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HOMEOSTASIS; HUMANS; INSULIN; MALE; MIDDLE AGED; NETHERLANDS; NITRILES; PEPTIDES; PHOSPHATES; POSTPRANDIAL PERIOD; PYRROLIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861128717     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2011.00168.x     Document Type: Article

References (11)

1. Clowes JA, Khosla S, Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res. 2005; 20: 1497-506.
2. Walsh JS, Henriksen DB. Feeding and bone. Arch Biochem Biophys. 2010; 503: 11-9.
3. Nuche Berenguer B, Portal-Núnez S, Moreno P et al. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol. 2010; 225: 585-92.
4. Bunck MC, Poelma M, Goede DL et al. Beta-cell function and glycemic control following one-year vildagliptin treatment, and after 12-week washout, in drug-naive patients with type 2 diabetes and mild hyperglycemia. Diabetologia. 2011; 54: 1985-91.
5. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab. 2000; 85: 3537-40.
6. Holst JJ, Hartmann B, Gottschalck IB et al. Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. Scand J Gastroenterol. 2007; 42: 814-20.
7. Yavropoulou MP, Tomos K, Tsekmekidou X et al. Response of biochemical markers of bone turnover to oral glucose load in diseases that affect bone metabolism. Eur J Endocrinol. 2011; 164: 1035-41.
8. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: A meta-analysis. Osteoporos Int. 2007; 18: 427-44.
9. Khazai NB, Beck GR Jr, Umpierrez GE. Diabetes and fractures: An overshadowed association. Curr Opin Endocrinol Diabetes Obes. 2009; 16: 435-45.
10. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005; 48: 1292-2299.
11. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-43.